Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)01430-8
Affiliations:
4
Authors:
13
Go to article
Institutions Authors Share
Johnson & Johnson, United States of America (USA)
11.000000
11.000000
 0.85
The University of Kansas (KU), United States of America (USA)
1.000000
 0.08
Immunopathologie et Chimie Thérapeutique, IBMC, France
1.000000
 0.08
Interested in Clinical Sciences?